Actively Recruiting
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
Led by dsm-firmenich Switzerland AG · Updated on 2026-03-11
236
Participants Needed
3
Research Sites
65 weeks
Total Duration
On this page
Sponsors
D
dsm-firmenich Switzerland AG
Lead Sponsor
A
Analyze & Realize
Collaborating Sponsor
AI-Summary
What this Trial Is About
To assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria) Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo
CONDITIONS
Official Title
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants aged 50 to 75 years inclusive
- Body Mass Index (BMI) between 18.5 and 32 kg/m2
- Generally in good health as judged by the investigator
- Subjective mild to moderate memory complaints
- Total score between 42 and 60 on the Depression Anxiety Stress Scale-21 (DASS-21) at baseline
- Willing to maintain regular diet, exercise, medication, supplement, and nicotine habits during the study
- Able to understand study procedures and provide informed consent
You will not qualify if you...
- History or presence of psychiatric or neurologic diseases that could affect study interpretation
- Mini-Mental State Examination (MMSE) score below 21 at baseline
- Chronic fatigue syndrome
- For women, stress or anxiety clearly related to menopausal complaints
- Started non-drug or non-supplement treatments for stress, anxiety, or memory complaints within 4 weeks prior to screening
- Significant gastrointestinal, endocrine, cardiovascular, kidney, liver, lung, pancreas, neurologic, or biliary disorders affecting study results
- Conditions likely to cause immunosuppression
- History of gastrointestinal surgery except gallbladder or appendix removal
- Uncontrolled high blood pressure at screening
- Hearing or vision issues interfering with study tasks
- Use of pre-, pro-, syn-, or post-biotic supplements within 90 days prior to screening
- Use of psychotropic, stimulant, or narcotic medications within 4 weeks prior to screening
- Major sleep disorders or recent use of sleep aids within 2 weeks prior to screening
- Use of acid-blocking medications in the 30 days before study start, except ongoing use started 12 weeks before
- Use of selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines in the 30 days before study
- History of cancer within 5 years
- Allergy to study product components or standardized breakfast
- Signs of active infection or recent antibiotic use within 30 days
- Exposure to unregistered drug products within 30 days
- Recent or potential illicit drug or excessive alcohol use
- Women who are pregnant, breastfeeding, or of childbearing potential not using reliable contraception
- Any condition interfering with consent, compliance, or study results interpretation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Biofortis
Paris, France, 75012
Actively Recruiting
2
Biofortis
Saint-Herblain, France, 44800
Actively Recruiting
3
analyze & realize GmbH
Berlin, Germany, 10369
Actively Recruiting
Research Team
L
Liana Vismane, DR
CONTACT
N
Natalie Doberstein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here